HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark C Genovese Selected Research

sarilumab

11/2021Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
10/2020Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
1/2020Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
1/2020Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
1/2019Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
1/2019Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
1/2018Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
1/2016Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
6/2015Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
9/2014Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark C Genovese Research Topics

Disease

117Rheumatoid Arthritis
04/2022 - 03/2002
37Infections
06/2022 - 05/2004
14Necrosis
01/2021 - 06/2007
12Psoriatic Arthritis
11/2021 - 05/2007
9Neoplasms (Cancer)
06/2022 - 01/2003
8Arthritis (Polyarthritis)
12/2021 - 09/2005
7Herpes Zoster
04/2022 - 01/2017
7Fatigue
01/2019 - 04/2006
6Psoriasis (Pustulosis Palmaris et Plantaris)
11/2021 - 05/2007
6Inflammation (Inflammations)
01/2020 - 05/2011
6Pain (Aches)
11/2019 - 04/2013
5Rheumatic Diseases (Rheumatism)
12/2021 - 01/2003
5Synovitis
01/2019 - 02/2011
5Chronic Disease (Chronic Diseases)
01/2019 - 09/2006
4Injection Site Reaction
12/2020 - 05/2004
4Headache (Headaches)
04/2020 - 03/2012
4Osteitis
01/2019 - 04/2011
4Neutropenia
01/2018 - 05/2004
3Respiratory Tract Infections (Respiratory Tract Infection)
04/2020 - 01/2018
3Autoimmune Diseases (Autoimmune Disease)
01/2009 - 03/2002
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
06/2005 - 03/2002
2Anemia
06/2022 - 04/2020
2Sarcoidosis (Schaumann Disease)
12/2021 - 01/2020
2Axial Spondyloarthritis
11/2021 - 12/2020
2Opportunistic Infections (Opportunistic Infection)
10/2020 - 01/2019
2Granulomatous Mastitis
01/2020 - 07/2009
2Nasopharyngitis
01/2019 - 01/2018
2Hypersensitivity (Allergy)
11/2018 - 11/2018
2Urinary Tract Infections (Urinary Tract Infection)
01/2018 - 03/2012
2Hypertension (High Blood Pressure)
12/2015 - 06/2005
2Ankylosing Spondylitis
01/2014 - 06/2007
1Venous Thromboembolism
06/2022
1Breakthrough Infections
10/2020
1Nausea
04/2020
1Heart Failure
01/2020
1Breast Diseases (Breast Disease)
01/2020

Drug/Important Bio-Agent (IBA)

48Methotrexate (Mexate)FDA LinkGeneric
01/2021 - 06/2002
22Antirheumatic Agents (DMARD)IBA
06/2022 - 09/2005
19Adalimumab (Humira)FDA Link
01/2021 - 05/2007
16Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2021 - 09/2005
12Monoclonal AntibodiesIBA
07/2021 - 09/2008
12baricitinibIBA
10/2020 - 02/2015
11Etanercept (Enbrel)FDA Link
01/2020 - 06/2002
10sarilumabIBA
11/2021 - 09/2014
10Biological ProductsIBA
01/2019 - 02/2011
9Tumor Necrosis Factor InhibitorsIBA
11/2021 - 06/2010
9Abatacept (Orencia)FDA Link
01/2018 - 09/2005
8golimumabFDA Link
02/2016 - 06/2010
6GLPG0634IBA
04/2022 - 01/2019
6ixekizumabIBA
11/2021 - 07/2014
6Biosimilar PharmaceuticalsIBA
11/2020 - 10/2017
6C-Reactive ProteinIBA
01/2019 - 10/2008
6tocilizumab (atlizumab)FDA Link
06/2017 - 10/2008
6ametantrone (HAQ)IBA
01/2017 - 09/2006
5Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
10/2020 - 10/2008
5Biomarkers (Surrogate Marker)IBA
01/2020 - 06/2005
5Janus Kinase InhibitorsIBA
12/2019 - 03/2012
5Interleukin-17 (Interleukin 17)IBA
11/2018 - 01/2012
5LipidsIBA
01/2017 - 01/2014
5fostamatinibIBA
12/2015 - 02/2011
4CytokinesIBA
01/2021 - 06/2007
4Infliximab (Remicade)FDA Link
01/2020 - 06/2004
4upadacitinibIBA
11/2019 - 12/2016
4AntigensIBA
01/2016 - 09/2005
4Syk KinaseIBA
12/2014 - 09/2010
4AutoantibodiesIBA
01/2009 - 03/2002
3omega-Chloroacetophenone (Mace)IBA
06/2022 - 01/2019
3InterleukinsIBA
07/2021 - 06/2007
3FKB327IBA
11/2020 - 12/2019
3Janus KinasesIBA
10/2020 - 01/2019
3Transaminases (Aminotransferases)IBA
01/2017 - 09/2014
3tofacitinibIBA
05/2016 - 03/2012
3secukinumabIBA
01/2016 - 06/2013
3CreatinineIBA
01/2016 - 04/2002
3tabalumabIBA
08/2015 - 09/2013
3B-Cell Activating FactorIBA
08/2015 - 09/2013
3Rituximab (Mabthera)FDA Link
06/2010 - 09/2006
2olokizumabIBA
07/2021 - 09/2014
2Agammaglobulinaemia Tyrosine KinaseIBA
01/2021 - 04/2020
2Interleukin-6 (Interleukin 6)IBA
01/2020 - 06/2007
2Pharmaceutical PreparationsIBA
12/2019 - 01/2019
2peficitinibIBA
12/2019 - 01/2017
2Creatine Kinase (Creatine Phosphokinase)IBA
11/2019 - 06/2007
2ABT-122IBA
11/2018 - 11/2018
2ChemokinesIBA
01/2018 - 06/2007
2Janus Kinase 1IBA
01/2018 - 03/2016
2Lipoproteins (Lipoprotein)IBA
01/2017 - 01/2016
22- ((2- (1H- pyrrolo(2,3- b)pyridin- 3- yl)pyrimidin- 4- yl)amino)- 2- methyl- N- (2,2,2- trifluoroethyl)butanamideIBA
11/2016 - 01/2016
2brodalumabIBA
02/2016 - 06/2014
2Phosphotransferases (Kinase)IBA
10/2015 - 10/2006
2Immunoglobulins (Immunoglobulin)IBA
08/2015 - 04/2002
2Interleukin-17 ReceptorsIBA
06/2014 - 01/2012
1poseltinibIBA
01/2021
1fenebrutinibIBA
04/2020
1Antiviral Agents (Antivirals)IBA
01/2020
1Blood Proteins (Serum Proteins)IBA
01/2020
1DNA (Deoxyribonucleic Acid)IBA
01/2020
1Glucose (Dextrose)FDA LinkGeneric
01/2020

Therapy/Procedure

36Therapeutics
07/2021 - 06/2002
2Biological Therapy
02/2011 - 06/2005